---
annotation-target: 1-s2.0-S0006497122010643-main.pdf
---


>%%
>```annotation-json
>{"created":"2022-09-13T06:11:24.211Z","updated":"2022-09-13T06:11:24.211Z","document":{"title":"GARP-mediated active TGF-β1 induces bone marrow NK cell dysfunction in AML patients with early relapse post-allo-HSCT","link":[{"href":"urn:x-pdf:7e54b41d5fc9c3c5e506c4bdfea5e2f8"},{"href":"vault:/hematology-theroy/papers/20220831/1-s2.0-S0006497122010643-main.pdf"}],"documentFingerprint":"7e54b41d5fc9c3c5e506c4bdfea5e2f8"},"uri":"vault:/hematology-theroy/papers/20220831/1-s2.0-S0006497122010643-main.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220831/1-s2.0-S0006497122010643-main.pdf","selector":[{"type":"TextPositionSelector","start":7785,"end":8094},{"type":"TextQuoteSelector","exact":" TGF-β1  activation  was 99 induced by the overexpression of glycoprotein A repetitions predominant (GARP) on 100 the  surface  of  CD4+  T  cells.  Active  TGF-β1  significantly  suppressed  mTORC1 101 activity, mitochondrial oxidative phosphorylation, the proliferation, and cytotoxicity 102 of BMNK cells. ","prefix":"ells  in  these  AML  patients. ","suffix":"Furthermore, pretreatment with t"}]}]}
>```
>%%
>*%%PREFIX%%ells  in  these  AML  patients.%%HIGHLIGHT%% ==TGF-β1  activation  was 99 induced by the overexpression of glycoprotein A repetitions predominant (GARP) on 100 the  surface  of  CD4+  T  cells.  Active  TGF-β1  significantly  suppressed  mTORC1 101 activity, mitochondrial oxidative phosphorylation, the proliferation, and cytotoxicity 102 of BMNK cells.== %%POSTFIX%%Furthermore, pretreatment with t*
>%%LINK%%[[#^lp1cxcgjvof|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^lp1cxcgjvof


>%%
>```annotation-json
>{"created":"2022-09-13T06:20:27.573Z","updated":"2022-09-13T06:20:27.573Z","document":{"title":"GARP-mediated active TGF-β1 induces bone marrow NK cell dysfunction in AML patients with early relapse post-allo-HSCT","link":[{"href":"urn:x-pdf:7e54b41d5fc9c3c5e506c4bdfea5e2f8"},{"href":"vault:/hematology-theroy/papers/20220831/1-s2.0-S0006497122010643-main.pdf"}],"documentFingerprint":"7e54b41d5fc9c3c5e506c4bdfea5e2f8"},"uri":"vault:/hematology-theroy/papers/20220831/1-s2.0-S0006497122010643-main.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220831/1-s2.0-S0006497122010643-main.pdf","selector":[{"type":"TextPositionSelector","start":8439,"end":8732},{"type":"TextQuoteSelector","exact":"our  findings  reveal  a  mechanism  explaining  BMNK  cell  dysfunction  and 107 suggest  that  targeted  inhibition  of  TGF-β1  signaling  may  represent  a  potential 108 therapeutic intervention to improve outcomes in AML patients undergoing allo-HSCT 109 or NK cell-based immunotherapy. ","prefix":"nograft mouse model. 106 Thus,  ","suffix":"110     111 Keywords: NK cells; "}]}]}
>```
>%%
>*%%PREFIX%%nograft mouse model. 106 Thus,%%HIGHLIGHT%% ==our  findings  reveal  a  mechanism  explaining  BMNK  cell  dysfunction  and 107 suggest  that  targeted  inhibition  of  TGF-β1  signaling  may  represent  a  potential 108 therapeutic intervention to improve outcomes in AML patients undergoing allo-HSCT 109 or NK cell-based immunotherapy.== %%POSTFIX%%110     111 Keywords: NK cells;*
>%%LINK%%[[#^vesq5ve4b|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^vesq5ve4b


>%%
>```annotation-json
>{"created":"2022-09-13T06:20:58.386Z","updated":"2022-09-13T06:20:58.386Z","document":{"title":"GARP-mediated active TGF-β1 induces bone marrow NK cell dysfunction in AML patients with early relapse post-allo-HSCT","link":[{"href":"urn:x-pdf:7e54b41d5fc9c3c5e506c4bdfea5e2f8"},{"href":"vault:/hematology-theroy/papers/20220831/1-s2.0-S0006497122010643-main.pdf"}],"documentFingerprint":"7e54b41d5fc9c3c5e506c4bdfea5e2f8"},"uri":"vault:/hematology-theroy/papers/20220831/1-s2.0-S0006497122010643-main.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220831/1-s2.0-S0006497122010643-main.pdf","selector":[{"type":"TextPositionSelector","start":9405,"end":9488},{"type":"TextQuoteSelector","exact":"Especially, after day 100 post-allo-HSCT, relapse becomes a primary cause of death4","prefix":"rticularly poor outcome4-7. 125 ","suffix":", 126 8. However, the underlying"}]}]}
>```
>%%
>*%%PREFIX%%rticularly poor outcome4-7. 125%%HIGHLIGHT%% ==Especially, after day 100 post-allo-HSCT, relapse becomes a primary cause of death4== %%POSTFIX%%, 126 8. However, the underlying*
>%%LINK%%[[#^sag3lp6o6g|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^sag3lp6o6g


>%%
>```annotation-json
>{"created":"2022-09-13T06:22:24.025Z","updated":"2022-09-13T06:22:24.025Z","document":{"title":"GARP-mediated active TGF-β1 induces bone marrow NK cell dysfunction in AML patients with early relapse post-allo-HSCT","link":[{"href":"urn:x-pdf:7e54b41d5fc9c3c5e506c4bdfea5e2f8"},{"href":"vault:/hematology-theroy/papers/20220831/1-s2.0-S0006497122010643-main.pdf"}],"documentFingerprint":"7e54b41d5fc9c3c5e506c4bdfea5e2f8"},"uri":"vault:/hematology-theroy/papers/20220831/1-s2.0-S0006497122010643-main.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220831/1-s2.0-S0006497122010643-main.pdf","selector":[{"type":"TextPositionSelector","start":9984,"end":10430},{"type":"TextQuoteSelector","exact":". NK cells are the first reconstituting lymphocytes and may represent up 133 to  80%  of  peripheral  blood  lymphocytes  during  the  first  100  days  after 134 transplantation10-14.  NK  cells  kill  leukemic  cells  via  the  exocytosis  of  granules 135 containing  cytolysis-related  proteins  such  as  Granzymes,  the  secretion  of  effector 136 cytokines  such  as  interferon-γ  (IFN-γ),  and  tumor  necrosis  factor  α  (TNF-α)13,  1","prefix":"de  immune  132 surveillance4, 9","suffix":"5. 137 However,  tumor  cells  o"}]}]}
>```
>%%
>*%%PREFIX%%de  immune  132 surveillance4, 9%%HIGHLIGHT%% ==. NK cells are the first reconstituting lymphocytes and may represent up 133 to  80%  of  peripheral  blood  lymphocytes  during  the  first  100  days  after 134 transplantation10-14.  NK  cells  kill  leukemic  cells  via  the  exocytosis  of  granules 135 containing  cytolysis-related  proteins  such  as  Granzymes,  the  secretion  of  effector 136 cytokines  such  as  interferon-γ  (IFN-γ),  and  tumor  necrosis  factor  α  (TNF-α)13,  1== %%POSTFIX%%5. 137 However,  tumor  cells  o*
>%%LINK%%[[#^r6ub6392hrl|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^r6ub6392hrl


>%%
>```annotation-json
>{"created":"2022-09-13T06:22:45.603Z","text":"Is there so called tumor microenvironment in AML?","updated":"2022-09-13T06:22:45.603Z","document":{"title":"GARP-mediated active TGF-β1 induces bone marrow NK cell dysfunction in AML patients with early relapse post-allo-HSCT","link":[{"href":"urn:x-pdf:7e54b41d5fc9c3c5e506c4bdfea5e2f8"},{"href":"vault:/hematology-theroy/papers/20220831/1-s2.0-S0006497122010643-main.pdf"}],"documentFingerprint":"7e54b41d5fc9c3c5e506c4bdfea5e2f8"},"uri":"vault:/hematology-theroy/papers/20220831/1-s2.0-S0006497122010643-main.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220831/1-s2.0-S0006497122010643-main.pdf","selector":[{"type":"TextPositionSelector","start":10542,"end":10567},{"type":"TextQuoteSelector","exact":"e tumor microenvironment ","prefix":"d  immune 138 surveillance in th","suffix":"due to the action of immunosuppr"}]}]}
>```
>%%
>*%%PREFIX%%d  immune 138 surveillance in th%%HIGHLIGHT%% ==e tumor microenvironment== %%POSTFIX%%due to the action of immunosuppr*
>%%LINK%%[[#^2ybbmja51wo|show annotation]]
>%%COMMENT%%
>Is there so called tumor microenvironment in AML?
>%%TAGS%%
>
^2ybbmja51wo


>%%
>```annotation-json
>{"created":"2022-09-13T06:23:37.527Z","text":"必要的","updated":"2022-09-13T06:23:37.527Z","document":{"title":"GARP-mediated active TGF-β1 induces bone marrow NK cell dysfunction in AML patients with early relapse post-allo-HSCT","link":[{"href":"urn:x-pdf:7e54b41d5fc9c3c5e506c4bdfea5e2f8"},{"href":"vault:/hematology-theroy/papers/20220831/1-s2.0-S0006497122010643-main.pdf"}],"documentFingerprint":"7e54b41d5fc9c3c5e506c4bdfea5e2f8"},"uri":"vault:/hematology-theroy/papers/20220831/1-s2.0-S0006497122010643-main.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220831/1-s2.0-S0006497122010643-main.pdf","selector":[{"type":"TextPositionSelector","start":10828,"end":10836},{"type":"TextQuoteSelector","exact":"ntegral ","prefix":"ors9.   142 TGF-β1  plays  an  i","suffix":" role  in  regulating  immune  r"}]}]}
>```
>%%
>*%%PREFIX%%ors9.   142 TGF-β1  plays  an  i%%HIGHLIGHT%% ==ntegral== %%POSTFIX%%role  in  regulating  immune  r*
>%%LINK%%[[#^5k2w4b6qs6p|show annotation]]
>%%COMMENT%%
>必要的
>%%TAGS%%
>
^5k2w4b6qs6p


>%%
>```annotation-json
>{"created":"2022-09-13T06:27:25.006Z","text":"蛋白丝氨酸/苏氨酸磷酸酶\n二聚体","updated":"2022-09-13T06:27:25.006Z","document":{"title":"GARP-mediated active TGF-β1 induces bone marrow NK cell dysfunction in AML patients with early relapse post-allo-HSCT","link":[{"href":"urn:x-pdf:7e54b41d5fc9c3c5e506c4bdfea5e2f8"},{"href":"vault:/hematology-theroy/papers/20220831/1-s2.0-S0006497122010643-main.pdf"}],"documentFingerprint":"7e54b41d5fc9c3c5e506c4bdfea5e2f8"},"uri":"vault:/hematology-theroy/papers/20220831/1-s2.0-S0006497122010643-main.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220831/1-s2.0-S0006497122010643-main.pdf","selector":[{"type":"TextPositionSelector","start":10969,"end":11296},{"type":"TextQuoteSelector","exact":"This is 144 composed of two type I TGF-β (TGF-βRI, also known as ALK5) and two type II 145 TGF-β (TGF-βRII) receptor subunits. Both receptors are serine/threonine kinases20, 21. 146 TGF-β1 is produced  as an inactive dimeric complex that undergoes  activation and 147 processing  before  exerting  its  functional  effects22,  ","prefix":"GF-β receptor (TGF-βR) complex. ","suffix":"23.  Glycoprotein-A  repetitions"}]}]}
>```
>%%
>*%%PREFIX%%GF-β receptor (TGF-βR) complex.%%HIGHLIGHT%% ==This is 144 composed of two type I TGF-β (TGF-βRI, also known as ALK5) and two type II 145 TGF-β (TGF-βRII) receptor subunits. Both receptors are serine/threonine kinases20, 21. 146 TGF-β1 is produced  as an inactive dimeric complex that undergoes  activation and 147 processing  before  exerting  its  functional  effects22,== %%POSTFIX%%23.  Glycoprotein-A  repetitions*
>%%LINK%%[[#^ezhrk9nkbnb|show annotation]]
>%%COMMENT%%
>蛋白丝氨酸/苏氨酸磷酸酶
>二聚体
>%%TAGS%%
>
^ezhrk9nkbnb


>%%
>```annotation-json
>{"created":"2022-09-13T06:36:35.623Z","updated":"2022-09-13T06:36:35.623Z","document":{"title":"GARP-mediated active TGF-β1 induces bone marrow NK cell dysfunction in AML patients with early relapse post-allo-HSCT","link":[{"href":"urn:x-pdf:7e54b41d5fc9c3c5e506c4bdfea5e2f8"},{"href":"vault:/hematology-theroy/papers/20220831/1-s2.0-S0006497122010643-main.pdf"}],"documentFingerprint":"7e54b41d5fc9c3c5e506c4bdfea5e2f8"},"uri":"vault:/hematology-theroy/papers/20220831/1-s2.0-S0006497122010643-main.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220831/1-s2.0-S0006497122010643-main.pdf","selector":[{"type":"TextPositionSelector","start":12105,"end":12396},{"type":"TextQuoteSelector","exact":" However,  the  mechanisms  leading  to  the 157 dysfunction of bone marrow NK (BMNK) cells have not been fully characterized in 158 AML  patients.  Thus,  whether  the  inhibition  of  TGF-β1  signaling  could  restore 159 anti-tumor activity in patients with relapsing AML remains unclear.","prefix":" several  mouse  models20,  31. ","suffix":" 160 In this study, we performed"}]}]}
>```
>%%
>*%%PREFIX%%several  mouse  models20,  31.%%HIGHLIGHT%% ==However,  the  mechanisms  leading  to  the 157 dysfunction of bone marrow NK (BMNK) cells have not been fully characterized in 158 AML  patients.  Thus,  whether  the  inhibition  of  TGF-β1  signaling  could  restore 159 anti-tumor activity in patients with relapsing AML remains unclear.== %%POSTFIX%%160 In this study, we performed*
>%%LINK%%[[#^o9wo207rmeg|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^o9wo207rmeg


>%%
>```annotation-json
>{"created":"2022-09-13T06:39:04.069Z","updated":"2022-09-13T06:39:04.069Z","document":{"title":"GARP-mediated active TGF-β1 induces bone marrow NK cell dysfunction in AML patients with early relapse post-allo-HSCT","link":[{"href":"urn:x-pdf:7e54b41d5fc9c3c5e506c4bdfea5e2f8"},{"href":"vault:/hematology-theroy/papers/20220831/1-s2.0-S0006497122010643-main.pdf"}],"documentFingerprint":"7e54b41d5fc9c3c5e506c4bdfea5e2f8"},"uri":"vault:/hematology-theroy/papers/20220831/1-s2.0-S0006497122010643-main.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220831/1-s2.0-S0006497122010643-main.pdf","selector":[{"type":"TextPositionSelector","start":11659,"end":12099},{"type":"TextQuoteSelector","exact":". Blockade of the TGF-β1 pathway has 152 become an attractive approach to restore anti-tumor immunity29. Galunisertib is an 153 orally  administered  small  molecule  inhibitor  of  TGF-βR1  kinase.  It  abrogates  the 154 activation  of  the  canonical  TGF-β1  pathway  by  specifically  downregulating  the 155 phosphorylation of SMAD2. Its ability to inhibit the proliferation of tumor cells was 156 shown  in  several  mouse  models20,","prefix":" cells and CD8+ T cells18, 27-30","suffix":"  31.  However,  the  mechanisms"}]}]}
>```
>%%
>*%%PREFIX%%cells and CD8+ T cells18, 27-30%%HIGHLIGHT%% ==. Blockade of the TGF-β1 pathway has 152 become an attractive approach to restore anti-tumor immunity29. Galunisertib is an 153 orally  administered  small  molecule  inhibitor  of  TGF-βR1  kinase.  It  abrogates  the 154 activation  of  the  canonical  TGF-β1  pathway  by  specifically  downregulating  the 155 phosphorylation of SMAD2. Its ability to inhibit the proliferation of tumor cells was 156 shown  in  several  mouse  models20,== %%POSTFIX%%31.  However,  the  mechanisms*
>%%LINK%%[[#^jrzjgzktelh|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^jrzjgzktelh


>%%
>```annotation-json
>{"created":"2022-09-13T06:40:34.808Z","updated":"2022-09-13T06:40:34.808Z","document":{"title":"GARP-mediated active TGF-β1 induces bone marrow NK cell dysfunction in AML patients with early relapse post-allo-HSCT","link":[{"href":"urn:x-pdf:7e54b41d5fc9c3c5e506c4bdfea5e2f8"},{"href":"vault:/hematology-theroy/papers/20220831/1-s2.0-S0006497122010643-main.pdf"}],"documentFingerprint":"7e54b41d5fc9c3c5e506c4bdfea5e2f8"},"uri":"vault:/hematology-theroy/papers/20220831/1-s2.0-S0006497122010643-main.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220831/1-s2.0-S0006497122010643-main.pdf","selector":[{"type":"TextPositionSelector","start":14198,"end":14220},{"type":"TextQuoteSelector","exact":"Xenograft mouse models","prefix":"196 (USTCACUC1701038). 197  198 ","suffix":" and treatment 199 HL60 cells (5"}]}]}
>```
>%%
>*%%PREFIX%%196 (USTCACUC1701038). 197  198%%HIGHLIGHT%% ==Xenograft mouse models== %%POSTFIX%%and treatment 199 HL60 cells (5*
>%%LINK%%[[#^mjolylumjq|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^mjolylumjq


>%%
>```annotation-json
>{"created":"2022-09-13T06:43:03.783Z","updated":"2022-09-13T06:43:03.783Z","document":{"title":"GARP-mediated active TGF-β1 induces bone marrow NK cell dysfunction in AML patients with early relapse post-allo-HSCT","link":[{"href":"urn:x-pdf:7e54b41d5fc9c3c5e506c4bdfea5e2f8"},{"href":"vault:/hematology-theroy/papers/20220831/1-s2.0-S0006497122010643-main.pdf"}],"documentFingerprint":"7e54b41d5fc9c3c5e506c4bdfea5e2f8"},"uri":"vault:/hematology-theroy/papers/20220831/1-s2.0-S0006497122010643-main.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220831/1-s2.0-S0006497122010643-main.pdf","selector":[{"type":"TextPositionSelector","start":16406,"end":16609},{"type":"TextQuoteSelector","exact":"e  analyzed  the  survival  rates  of  173  AML  patients  (Supplementary Table 4) 228 from  the  Gene  Expression  Profiling  Interactive  Analysis  (GEPIA)  database 229 (http://gepia.cancer-pku.cn)35.","prefix":"225  226 Survival analysis 227 W","suffix":"  The  patients  were  classifie"}]}]}
>```
>%%
>*%%PREFIX%%225  226 Survival analysis 227 W%%HIGHLIGHT%% ==e  analyzed  the  survival  rates  of  173  AML  patients  (Supplementary Table 4) 228 from  the  Gene  Expression  Profiling  Interactive  Analysis  (GEPIA)  database 229 (http://gepia.cancer-pku.cn)35.== %%POSTFIX%%The  patients  were  classifie*
>%%LINK%%[[#^vdhel6vliz|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^vdhel6vliz


>%%
>```annotation-json
>{"created":"2022-09-13T06:43:36.050Z","updated":"2022-09-13T06:43:36.050Z","document":{"title":"GARP-mediated active TGF-β1 induces bone marrow NK cell dysfunction in AML patients with early relapse post-allo-HSCT","link":[{"href":"urn:x-pdf:7e54b41d5fc9c3c5e506c4bdfea5e2f8"},{"href":"vault:/hematology-theroy/papers/20220831/1-s2.0-S0006497122010643-main.pdf"}],"documentFingerprint":"7e54b41d5fc9c3c5e506c4bdfea5e2f8"},"uri":"vault:/hematology-theroy/papers/20220831/1-s2.0-S0006497122010643-main.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220831/1-s2.0-S0006497122010643-main.pdf","selector":[{"type":"TextPositionSelector","start":16950,"end":17210},{"type":"TextQuoteSelector","exact":"We used two-tailed unpaired or paired Student’s t-tests between two groups, one-way 236 analysis of variance (ANOVA) across multiple groups, the Mann–Whitney U test for 237 continuous variables, and Chi-Squared and Fisher exact tests for categorical variables,","prefix":"3  234 Statistical analysis 235 ","suffix":" 238 9  and the Wilcoxon signed "}]}]}
>```
>%%
>*%%PREFIX%%3  234 Statistical analysis 235%%HIGHLIGHT%% ==We used two-tailed unpaired or paired Student’s t-tests between two groups, one-way 236 analysis of variance (ANOVA) across multiple groups, the Mann–Whitney U test for 237 continuous variables, and Chi-Squared and Fisher exact tests for categorical variables,== %%POSTFIX%%238 9  and the Wilcoxon signed*
>%%LINK%%[[#^hgqi1lalwx|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^hgqi1lalwx
